Celgene Corp. buy klostergang
Summary
This prediction ended on 10.03.20 with a price of -. The prediction for Celgene Corp. disappointed with a performance of -22.99%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by klostergang for this prediction
In the thread Celgene Corp. diskutieren
Celgene is positioned to continue double digit growth beyond 2020...
klostergang stimmt am 06.10.2017 der Buy-Einschätzung von tamam mit dem Kursziel 141,04$ zu.
Überschrift: Celgene is a true "buy & hold" name in the biotech sector
Celgene has positioned itself as a market leader in the the multiple myeloma market, and has fifty six different projects in development in Phase I, II and III trial stages. The pipeline addresses diverse
therapeutic applications including inflammation and gastro intestinal, central nervous system, tumors and hematology. Most importantly, the patents of all its blockbuster products are not expiring for the next four years. Considering these factors, the EPS growth discussed above and the upcoming catalysts through 2020, Celgene could be $200 stock in a couple of years. For the 12 month horizon, based on the H2 2017 and 2018 EPS estimates, I believe there is a 20% upside and the stock price could reach $174.